Last reviewed · How we verify
GLPG3667 capsules
At a glance
| Generic name | GLPG3667 capsules |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (PHASE2)
- A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (PHASE2)
- A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667 (PHASE1)
- Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667 (PHASE1)
- A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects (PHASE1)
- A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis (PHASE1)
- Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG3667 capsules CI brief — competitive landscape report
- GLPG3667 capsules updates RSS · CI watch RSS
- Galapagos NV portfolio CI